The Lancet. Respiratory medicineAdultAgedFemaleHumansMale
Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
Eugenio De Corso, G Walter Canonica, Enrico Heffler, Michal Springer, Tomasz Grzegorzek, Miguel Viana, Zsuzsanna Horváth, Joaquim Mullol, Philippe Gevaert, Justin Michel, Anju T Peters, Martin Wagenmann, Sherif Zaghloul, Mei Zhang, Mark Corbett
Published: 202510.1016/S2213-2600(25)00287-5
Abstract
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly driven by type 2 inflammation. The biologics dupilumab and omalizumab, which target drivers and mediators of type 2 inflammation (interleukin [IL]-4/IL-13 signaling and im…
Preview only. Read the full abstract at the source